Compare DMRA & CSWC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRA | CSWC |
|---|---|---|
| Founded | 2011 | 1961 |
| Country | United States | United States |
| Employees | 7 | 36 |
| Industry | Biotechnology: Pharmaceutical Preparations | Textiles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2020 | N/A |
| Metric | DMRA | CSWC |
|---|---|---|
| Price | $21.40 | $23.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $43.00 | $23.50 |
| AVG Volume (30 Days) | 356.8K | ★ 576.0K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 10.89% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.45 |
| Revenue Next Year | N/A | $10.26 |
| P/E Ratio | ★ N/A | $12.65 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.50 | $19.37 |
| 52 Week High | $28.76 | $24.43 |
| Indicator | DMRA | CSWC |
|---|---|---|
| Relative Strength Index (RSI) | 31.88 | 47.33 |
| Support Level | $16.50 | $22.59 |
| Resistance Level | $26.66 | $23.84 |
| Average True Range (ATR) | 1.61 | 0.40 |
| MACD | -0.37 | -0.01 |
| Stochastic Oscillator | 13.54 | 45.90 |
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source of revenue comprises interest income and dividend income from investments made as well as management fees.